



**Shield Therapeutics plc
("Shield" or the "Company")**

Appointment of Non-Executive Director

London, UK, 6 April 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Rolf Hoffmann, as a Non-Executive Director of the Company with immediate effect. Mr Hoffmann is currently Chairman of Biotest AG, sits on the Board of Directors of the large European biotechnology company Genmab AG and is a Director of San Francisco-based Trigemina Inc.

Rolf brings to Shield over 30 years of international pharmaceutical experience having served in several senior roles in the industry, most recently 12 years with Amgen as Senior Vice President of Commercial Operations for the United States, and before that as SVP International and Europe. He started his pharmaceutical career at Eli Lilly as a sales representative, progressing to senior positions including President of Latin America operations and General Manager in Germany. Rolf holds an MBA from the University of North Carolina, a master's degree from the University of Cologne and is Adjunct Professor at UNC Kenan-Flagler Business School.

Andrew Heath, Chairman of Shield Therapeutics, said: "I am delighted to welcome Rolf to the Board of Shield Therapeutics. His extensive experience and knowledge of the pharmaceutical industry and its key stakeholders in major markets will be helpful in defining the Company's future strategy and we look forward to Rolf playing a full and active role in these discussions and beyond."

Regulatory Disclosures

The following disclosures are required regarding Rolf's appointment pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name and age: Rolf Karl Heinz Hoffmann, aged 58

Schedule of directorships and previous directorships (resigned within the last five years):

Current Directorships

Biotest AG
EUSA
Genmab AG
German-American Heritage Foundation
NavBio AG
Stada AG
Trigemeninia Inc.
US Health Leadership Council
World Anti-Doping Agency

Former Directorships

Amgen Australia Pty Limited
Amgen (Middle East) FZ LCC
Amgen (Middle East) FZ LLC
Amgen (New Zealand) Limited
Amgen (New Zealand) Limited
Amgen AB Norge
Amgen Australia Pty Limited
Amgen Australia Pty Limited New Zealand
Amgen Europe B.V., Israel Branch
Amgen Filial AF Amgen Aktiebolag, Sverige
Amgen Inc.
Amgen Inc.
Amgen Latin America Services, S.A. de C.V.
Amgen Latin America Services, S.A. de C.V.



Amgen Mexico, S.A. de C.V.
Amgen Romania srl
Amgen S.p.A.
Amgen Singapore Pte, Ltd.
Amgen South Eastern Europe Operations
S.r.l.
Amgen Switzerland AG Luzern Podruznic
Ljubljana
Amgen Switzerland AG Rigas filiale
Amgen Switzerland AG Rigas filiale
Amgen Switzerland AG Slovakia
Amgen Switzerland AG Vilinius filialas
Amgen Switzerland AG Vilinius filialas
Amgen Technology Private Limited
Amgen Technology Private Limited
Amgen USA Inc.
Amgen USA Inc.
Immunex Corporation
Immunex Corporation
Immunex Rhode Island Corporation
Immunex Rhode Island Corporation
Tularik Limited

No further disclosure is required under AIM Rule 17 and paragraph (g) to Schedule Two of the AIM Rules with respect to Rolf Hoffmann.

- Ends -

For further information please contact:

Shield Therapeutics plc +44 (0)207 186 8500

Carl Sterritt, Chief Executive Officer
Dr Karl Keegan, Chief Financial Officer
Fleur Wood, Director, Investor Relations

Nominated Advisor and Joint Broker +44 (0)203 100 2222

Liberum Capital Limited
Christopher Britton/Steve Pearce

Joint Broker +44 (0)207 418 8900

Peel Hunt LLP
James Steel/ Dr Christopher Golden

Financial PR Advisor +44 (0)203 709 5700

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc



Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru[®], for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.